High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease

Bibliography

• GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110(2):227-239.
   PubMed Web of Science ®Google Scholar
• DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al.: European guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis (2004) 173(2):381-391.
   PubMed Web of Science ®Google Scholar
• CHOLESTEROL TREATMENT TRIALISTS COLLABORATORS: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366(9493):1267-1278.
   PubMed Web of Science ®Google Scholar
• BARR DP, RUSS EM, EDER HA: Protein-lipid relationships in human plasma. Am. J. Med. (1951) 11:480-485.
   PubMed Web of Science ®Google Scholar
• GOFMAN JW, YOUNG W, TANDY R: Ischemic heart disease, atherosclerosis, and longevity. Circulation (1966) 34:679-697.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, RIFKIND BM: High density lipoprotein: the clinical implications of recent studies. N. Engl. J. Med. (1989) 321:1311-1316.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, PROBSTFIELD JL, GARRISON RJ et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 79(1):8-15.
   PubMed Web of Science ®Google Scholar
• BERGE KG, CANNER PL, HAINLINE A Jr: High-density lipoprotein cholesterol and prognosis after myocardial infarction. Circulation (1982) 66:1176-1178.
   PubMed Web of Science ®Google Scholar
• OLSSON AG, SCHWARTZ GG, SZAREK M et al.: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur. Heart J. (2005) 26(9):890-896.
   PubMed Web of Science ®Google Scholar
• BALDASSARRE D, AMATO M, PUSTINA L et al.: Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. (2002) 22(2):317-322.
   PubMed Web of Science ®Google Scholar
• MATHIESEN EB, BONAA KH, JOAKIMSEN O: Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the Tromso study. Stroke (2001) 32:1960-1965.
   PubMed Web of Science ®Google Scholar
• JOHNSEN SH, MATHIESEN EB, FOSSE E et al.: Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study. Circulation (2005) 112(4):498-504.
   PubMed Web of Science ®Google Scholar
• RUBIN EM, KRAUSS RM, SPANGLER EA, VERSTUYFT JG, CLIFT SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (1991) 353:265-267.
   PubMed Web of Science ®Google Scholar
• PASZTY C, MAEDA N, VERSTUYFT J, RUBIN EM: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. (1994) 94:899-903.
   PubMed Web of Science ®Google Scholar
• LEWIS GF, RADER DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. (2005) 96(12):1221-1232.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, GOMARASCHI M, FRANCESCHINI G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. (2003) 23(10):1724-1731.
   PubMed Web of Science ®Google Scholar
• MACKNESS MI, DURRINGTON PN, MACKNESS B: How high-density lipoprotein protects against the effects of lipid peroxidation. Curr. Opin. Lipidol. (2000) 11:383-388.
   PubMed Web of Science ®Google Scholar
• ROSENSON RS: Low HDL-C: a secondary target of dyslipidemia therapy. Am. J. Med. (2005) 118(10):1067-1077.
   PubMedGoogle Scholar
• RYE KA, BARTER PJ: Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. (2004) 24(3):421-428.
   PubMed Web of Science ®Google Scholar
• IKEWAKI K, RADER DJ, SCHAEFER JR, FAIRWELL T, ZECH LA, BREWER HB, Jr: Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J. Lipid Res. (1993) 34:2207-2215.
   PubMed Web of Science ®Google Scholar
• HUUSKONEN J, OLKKONEN VM, JAUHIAINEN M, EHNHOLM C: The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis (2001) 155:269-281.
   PubMed Web of Science ®Google Scholar
• CHISHOLM JW, BURLESON ER, SHELNESS GS, PARKS JS: ApoA-I secretion from HepG2 cells. Evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J. Lipid Res. (2002) 43(1):36-44.
   PubMed Web of Science ®Google Scholar
• TSUJITA M, WU CA, BE-DOHMAE S, USUI S, OKAZAKI M, YOKOYAMA S: On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J. Lipid Res. (2005) 46(1):154-162.
   PubMed Web of Science ®Google Scholar
• WEBB NR, DE BEER MC, ASZTALOS BF, WHITAKER N, VAN DER WESTHUYZEN DR, DE BEER FC: Remodeling of HDL remnants generated by scavenger receptor class B Type I. J. Lipid Res. (2004) 45(9):1666-1673.
   PubMedGoogle Scholar
• ECKHARDT ER, CAI L, SUN B, WEBB NR, VAN DER WESTHUYZEN DR: High density lipoprotein uptake by scavenger receptor SR-BII. J. Biol. Chem. (2004) 279(14):14372-14381.
   PubMed Web of Science ®Google Scholar
• MARTINEZ LO, JACQUET S, ESTEVE JP et al.: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature (2003) 421(6918):75-79.
   PubMed Web of Science ®Google Scholar
• MOESTRUP SK, NIELSEN LB: The role of the kidney in lipid metabolism. Curr. Opin. Lipidol. (2005) 16(3):301-306.
   PubMed Web of Science ®Google Scholar
• MOORE RE, NAVAB M, MILLAR JS et al.: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. (2005) 97(8):763-771.
   PubMed Web of Science ®Google Scholar
• STEINBERG D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8(11):1211-1217.
   PubMed Web of Science ®Google Scholar
• FAVARI E, LEE M, CALABRESI L et al.: Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J. Biol. Chem. (2004) 279(11):9930-9936.
   PubMedGoogle Scholar
• YANCEY PG, BORTNICK AE, KELLNER-WEIBEL G, LLERA-MOYA M, PHILLIPS MC, ROTHBLAT GH: Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. (2003) 23(5):712-719.
   PubMed Web of Science ®Google Scholar
• WANG N, LAN D, CHEN W, MATSUURA F, TALL AR: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA (2004) 101(26):9774-9779.
   PubMed Web of Science ®Google Scholar
• TANG C, VAUGHAN AM, ORAM JF: Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J. Biol. Chem. (2004) 279(9):7622-7628.
   PubMedGoogle Scholar
• YU L, HAMMER RE, LI-HAWKINS J et al.: Disruption of ABCG5 and ABCG8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. USA (2002) 99(25):16237-16242.
   PubMed Web of Science ®Google Scholar
• JI Y, WANG N, RAMAKRISHNAN R et al.: Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J. Biol. Chem. (1999) 274:33398-33402.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, ZANOTTI I, REILLY MP, GLICK JM, ROTHBLAT GH, RADER DJ: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 108(6):661-663.
   PubMed Web of Science ®Google Scholar
• GROEN AK, BLOKS VW, BANDSMA RH, OTTENHOFF R, CHIMINI G, KUIPERS F: Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J. Clin. Invest. (2001) 108:843-850.
   PubMed Web of Science ®Google Scholar
• DROBNIK W, LINDENTHAL B, LIESER B et al.: ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Gastroenterology (2001) 120:1203-1211.
   PubMed Web of Science ®Google Scholar
• FRANCONE OL, ROYER L, BOUCHER G et al.: Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler. Thromb. Vasc. Biol. (2005) 25(6):1198-1205.
   PubMed Web of Science ®Google Scholar
• CALPE-BERDIEL L, ROTLLAN N, PALOMER X, RIBAS V, BLANCO-VACA F, ESCOLA-GIL JC: Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim. Biophys. Acta (2005) 1738(1-3):6-9.
   PubMedGoogle Scholar
• VAISMAN BL, LAMBERT G, AMAR M et al.: ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. (2001) 108:303-309.
   PubMed Web of Science ®Google Scholar
• VAN ECK M, PENNINGS M, HOEKSTRA M, OUT R, VAN BERKEL TJ: Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr. Opin. Lipidol. (2005) 16(3):307-315.
   PubMed Web of Science ®Google Scholar
• WANG N, ARAI T, JI Y, RINNINGER F, TALL AR: Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J. Biol. Chem. (1998) 273(49):32920-32926.
   PubMed Web of Science ®Google Scholar
• SHAH PK, YANO J, REYES O et al.: High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation (2001) 103:3047-3050.
   PubMed Web of Science ®Google Scholar
• CHIESA G, MONTEGGIA E, MARCHESI M et al.: Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. (2002) 90(9):974-980.
   PubMed Web of Science ®Google Scholar
• ERIKSSON M, CARLSON LA, MIETTINEN TA, ANGELIN B: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation (1999) 100:594-598.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, COOKE CJ, GARVIN R et al.: Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. (2001) 42:1586-1593.
   PubMed Web of Science ®Google Scholar
• BONETTI PO, LERMAN LO, LERMAN A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. (2003) 23(2):168-175.
   PubMed Web of Science ®Google Scholar
• ASSANASEN C, MINEO C, SEETHARAM D et al.: Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J. Clin. Invest. (2005) 115(4):969-977.
   PubMed Web of Science ®Google Scholar
• DREW BG, FIDGE NH, GALLON-BEAUMIER G, KEMP BE, KINGWELL BA: High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl. Acad. Sci. USA (2004) 101(18):6999-7004.
   PubMed Web of Science ®Google Scholar
• NOFER JR, VAN DER GM, TOLLE M et al.: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. (2004) 113(4):569-581.
   PubMed Web of Science ®Google Scholar
• KUVIN JT, RAMET ME, PATEL AR, PANDIAN NG, MENDELSOHN ME, KARAS RH: A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J. (2002) 144(1):165-172.
   PubMed Web of Science ®Google Scholar
• RAMET ME, RAMET M, LU Q et al.: High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. (2003) 41(12):2288-2297.
   PubMed Web of Science ®Google Scholar
• SPIEKER LE, SUDANO I, HURLIMANN D et al.: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 105(12):1399-1402.
   PubMed Web of Science ®Google Scholar
• BISOENDIAL RJ, HOVINGH GK, LEVELS JH et al.: Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 107(23):2944-2948.
   PubMed Web of Science ®Google Scholar
• VAN SICKLE WA, WILCOX HG, MALIK KU, NASJLETTI A: High density lipoprotein-induced cardiac prostacyclin synthesis in vitro: relationship to cardiac arachidonate mobilization. J. Lipid Res. (1986) 27(5):517-522.
   PubMedGoogle Scholar
• CALABRESI L, ROSSONI G, GOMARASCHI M, SISTO F, BERTI F, FRANCESCHINI G: High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ. Res. (2003) 92(3):330-337.
   PubMed Web of Science ®Google Scholar
• BARTER PJ, BAKER PW, RYE KA: Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol. (2002) 13(3):285-288.
   PubMed Web of Science ®Google Scholar
• XIA P, VADAS MA, RYE KA, BARTER PJ, GAMBLE JR: High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. (1999) 274:33143-33147.
   PubMed Web of Science ®Google Scholar
• NAVAB M, IMES SS, HAMA SY et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. (1991) 88:2039-2046.
   PubMed Web of Science ®Google Scholar
• GOMARASCHI M, BASILICO N, SISTO F et al.: High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim. Biophys. Acta (2005) 1736(2):136-143.
   PubMed Web of Science ®Google Scholar
• NORATA GD, CALLEGARI E, MARCHESI M, CHIESA G, ERIKSSON P, CATAPANO AL: High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation (2005) 111(21):2805-2811.
   PubMed Web of Science ®Google Scholar
• THEILMEIER G, DE GEEST B, VAN VELDHOVEN PP et al.: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. (2000) 14:2032-2039.
   PubMed Web of Science ®Google Scholar
• RONG JX, LI J, REIS ED, CHOUDHURY RP et al.: Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation (2001) 104:2447-2452.
   PubMed Web of Science ®Google Scholar
• COCKERILL GW, HUEHNS TY, WEERASINGHE A et al.: Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation (2001) 103:108-112.
   PubMed Web of Science ®Google Scholar
• COCKERILL GW, MCDONALD MC, MOTA-FILIPE H, CUZZOCREA S, MILLER NE, THIEMERMANN C: High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J. (2001) 15:1941-1952.
   PubMed Web of Science ®Google Scholar
• CUZZOCREA S, DUGO L, PATEL NS et al.: High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock (2004) 21(4):342-351.
   PubMedGoogle Scholar
• DIMAYUGA P, ZHU J, OGUCHI S et al.: Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff- induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun. (1999) 264:465-468.
   PubMed Web of Science ®Google Scholar
• NICHOLLS SJ, DUSTING GJ, CUTRI B et al.: Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation (2005) 111(12):1543-1550.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, GOMARASCHI M, VILLA B, OMOBONI L, DMITRIEFF C, FRANCESCHINI G: Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. (2002) 22:656-661.
   PubMed Web of Science ®Google Scholar
• SAMPIETRO T, BIGAZZI F, DAL PINO B et al.: Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation (2002) 105(1):11-14.
   PubMed Web of Science ®Google Scholar
• MERTENS A, HOLVOET P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. (2001) 15:2073-2084.
   PubMed Web of Science ®Google Scholar
• NAVAB M, ANANTHRAMAIAH GM, REDDY ST et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. (2004) 45(6):993-1007.
   PubMed Web of Science ®Google Scholar
• SATTLER W, STOCKER R: Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. Biochem. J. (1993) 294:771-778.
   PubMed Web of Science ®Google Scholar
• MARATHE GK, ZIMMERMAN GA, MCINTYRE TM: Platelet-activating factor acetylhydrolase, and not paraoxonase-1, Is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. (2003) 278(6):3937-3947.
   PubMed Web of Science ®Google Scholar
• VOHL MC, NEVILLE TA, KUMARATHASAN R, BRASCHI S, SPARKS DL: A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry (1999) 38:5976-5981.
   PubMedGoogle Scholar
• GOYAL J, WANG K, LIU M, SUBBAIAH PV: Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J. Biol. Chem. (1997) 272:16231-16239.
   PubMedGoogle Scholar
• GARNER B, WALDECK AR, WITTING PK, RYE KA, STOCKER R: Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. (1998) 273:6088-6095.
   PubMed Web of Science ®Google Scholar
• TOTH PP: High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol. (2005) 96(9A):50K-58K.
   PubMed Web of Science ®Google Scholar
• LINSEL-NITSCHKE P, TALL AR: HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. (2005) 4(3):193-205.
   PubMed Web of Science ®Google Scholar
• NAVAB M, ANANTHARAMAIAH GM, REDDY ST et al.: Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr. Opin. Lipidol. (2004) 15(6):645-649.
   PubMed Web of Science ®Google Scholar
• SHAH PK, CHYU KY: Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc. Med. (2005) 15(8):291-296.
   PubMedGoogle Scholar
• INAZU A, BROWN ML, HESLER CB et al.: Increased high density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. (1990) 323:1234-1238.
   PubMed Web of Science ®Google Scholar
• CLARK RW, SUTFIN TA, RUGGERI RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. (2004) 24(3):490-497.
   PubMed Web of Science ®Google Scholar
• DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation (2002) 105(18):2159-2165.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. (2004) 350(15):1505-1515.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, DIFFENDERFER MR, MILLAR JS et al.: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. (2005) 25(5):1057-1064.
   PubMed Web of Science ®Google Scholar
• KUIVENHOVEN JA, DE GROOTH GJ, KAWAMURA H et al.: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. (2005) 95(9):1085-1088.
   PubMed Web of Science ®Google Scholar
• RITTERSHAUS CW, MILLER DP, THOMAS LJ et al.: Vaccine-induced antibodies inhibit CETP activity In vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2106-2112.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, MAKI K, UMPOROWICZ D, WHEELER A, RITTERSHAUS C, RYAN U: The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis (2003) 169(1):113-120.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ CC, VANDENBROEK JM, COOPER PS: Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. (2004) 45(9):1594-1607.
   PubMed Web of Science ®Google Scholar
• FORRESTER JS, MAKKAR R, SHAH PK: Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation (2005) 111(14):1847-1854.
   PubMedGoogle Scholar
• ZHONG S, SHARP DS, GROVE JS et al.: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. (1996) 97:2917-2923.
   PubMed Web of Science ®Google Scholar
• MORIYAMA Y, OKAMURA T, INAZU A et al.: A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. (1998) 27:659-667.
   PubMed Web of Science ®Google Scholar
• ZHANG B, FAN P, SHIMOJI EC et al.: Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler. Thromb. Vasc. Biol. (2004) 24(10):1910-1915.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, YONEMORI F, WAKITANI K, MINOWA T, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203-207.
   PubMed Web of Science ®Google Scholar
• HUANG Z, INAZU A, NOHARA A, HIGASHIKATA T, MABUCHI H: Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (2002) 103(6):587-594.
   PubMed Web of Science ®Google Scholar
• MOREHOUSE LA, SUGARMAN ED, BOURASSA PA, MILICI AJ: HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. Circulation (2004) 110:1168.
   PubMedGoogle Scholar
• GAOFU Q, JUN L, XIN Y et al.: Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions In vivo. J. Cardiovasc. Pharmacol. (2005) 45(6):591-598.
   PubMed Web of Science ®Google Scholar
• BADIMON JJ, BADIMON L, FUSTER V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. (1990) 85:1234-1241.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, GOMARASCHI M, ROSSONI G, FRANCESCHINI G: Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury. Pharmacol. Ther. (2006) In Press.
   PubMedGoogle Scholar
• NISSEN SE, TSUNODA T, TUZCU EM, SCHOENHAGEN P et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 290(17):2292-2300.
   PubMed Web of Science ®Google Scholar
• SIRTORI CR, CALABRESI L, FRANCESCHINI G: Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis (1999) 142:29-40.
   PubMedGoogle Scholar
• CHIESA G, SIRTORI CR: Apolipoprotein A-I(Milano): current perspectives. Curr. Opin. Lipidol. (2003) 14(2):159-163.
   PubMed Web of Science ®Google Scholar
• RADER DJ: High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA (2003) 290(17):2322-2324.
   PubMed Web of Science ®Google Scholar